<DOC>
	<DOCNO>NCT02080858</DOCNO>
	<brief_summary>Background : The acute coronary syndrome ( ACS ) complication coronary artery disease ( CAD ) associate increased mortality . Dual antiplatelet therapy acetylsalicylic acid ( ASA ) P2Y12 receptor antagonist clopidogrel cornerstone treatment patient advance CAD . Due delay onset action , intersubject variability resistance clopidogrel , different platelet aggregation inhibitor develop . Ticagrelor reversible P2Y12 receptor antagonist superior efficacy compare clopidogrel prevention cardiovascular death patient . Atrial fibrillation ( AF ) also associate thromboembolic event substantial mortality . Beside vitamin K antagonist ( VKA , phenprocoumon ) stroke prevention patient AF , direct factor Xa inhibitor apixaban recently receive approval prophylactic treatment patient non-valvular AF . However , lack efficacy safety data combine impact antithrombotic drug patient require arterial venous thromboembolic prophylaxis due underlie co-morbidities . One trial suggest treatment VKA + clopidogrel without ASA equal effective antithrombotic triple therapy ( ASA ) population . However , effect combination novel oral anticoagulant investigate far . Study objectives : To evaluate effect ticagrelor + apixaban combination without ASA steady state marker coagulation activation thrombus size ex vivo perfusion chamber experiment . Additionally , plasma sample analyse PK-data ( ticagrelor &amp; apixaban concentration ) Study design : A single-centre , prospective , sequential , control , analyst-blinded study two group . Subjects receive ticagrelor + apixaban combination ( study A ) without ( study B ) ASA . All IMPs administer dos indicate stroke prevention AF ( low dose : 2.5mg due ethical concern ) ACS . Markers thrombin generation platelet activation study venous blood coagulation rest state shed blood clotting system activate microvasculature vivo : prothrombin fragment 1+2 ( F1+2 ) , thrombin-anti-thrombin ( TAT ) , β-thromboglobulin ( β-TG ) . Additionally , inhibition factor Xa activity concentration ticagrelor apixaban assess venous blood . Further , thrombus size clot form ex vivo perfusion chamber determine measurement D-Dimer p-Selectin level . Study population A total 40 healthy , non-smoking drug-free male volunteer enrol ( study A B ; n = 20 per group ) . Main outcome variable : - β-TG shed blood Additional outcome variable : - F1+2 TAT shed blood - fibrin formation ( D-Dimer ) platelet deposition ( p-Selectin ) ex vivo perfusion chamber model thrombosis - β-TG , F1+2 , TAT &amp; inhibition factor Xa venous blood - PT , aPTT ACT venous blood - ticagrelor &amp; apixaban plasma concentration - shed blood volume</brief_summary>
	<brief_title>Triple vs. Dual Therapy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male subject ; 18 40 year age body mass index 18 27 kg/m2 Written inform consent Normal find medical &amp; bleed history Nonsmoking behaviour Regular intake medication include OTC drug herbal within 2 week IMP administration Known coagulation disorder ( e.g . haemophilia , von Willebrand´s disease ) Known disorder increase bleed risk ( e.g . peridontitis , haemorrhoid , acute gastritis , peptic ulcer , intestinal ulcer ) Known sensitivity common cause bleeding ( e.g . nasal ) History thromboembolism Anaemia ( define haemoglobin level &lt; LLN ) Impaired liver function ( AST , ALT , GGT &gt; 2 x ULN , Bilirubin &gt; 1.5 x ULN ) Impaired renal function ( serum creatinine &gt; 1.3 mg/dl ) Any relevant deviation normal range clinical chemistry , haematology urine analysis HIV1/2Ab , HbsAg HCVAb positive serology Systolic blood pressure 145 mmHg , diastolic blood pressure 95 mmHg Known allergy test agent Regular daily consumption litre xanthinecontaining beverage 40g alcohol Participation another clinical trial precede 3 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Apixaban</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>ASA</keyword>
	<keyword>shed blood</keyword>
	<keyword>perfusion chamber</keyword>
</DOC>